Study shows path to 'dial down' autoimmunity without compromising immune response

January 19, 2016, The Scripps Research Institute

A new study led by scientists at The Scripps Research Institute (TSRI) shows how dangerous autoimmune responses, seen in diseases such as lupus and multiple sclerosis, might be "dialed down" without compromising the immune system's ability to fight viruses and bacteria.

The new study, published this week in the Early Edition of the journal Proceedings of the National Academy of Sciences, defines an unexpected mechanism at work in an anti-autoimmune drug candidate called ozanimod (now under development by Celgene).

"The study uses a proof-of-concept tool compound called CYM-5442," said TSRI Professor Hugh Rosen, who led the new study with TSRI colleagues Professor Michael Oldstone and Assistant Professor John Teijaro. "With this tool, we show a new, important mechanism in disease that can prevent collateral tissue damage while preserving the protective host response. The findings suggest one could optimize drugs for their ability to suppress this pathway."

In Success, a Mystery

Rosen has long been interested in a cell membrane protein, called the sphingosine 1-phosphate receptor 1 (S1PR1), as a promising target for autoimmune diseases.

In 2008, Rosen and his colleague, TSRI Professor Ed Roberts, identified a molecule that acts as an S1PR1 receptor "agonist"—inhibiting S1PR1 signaling and blocking a source of inflammation. The discovery led to the development of ozanimod, which is currently in advanced phase 3 clinical trials for multiple sclerosis and ulcerative colitis.

The initial clinical trials, however, led to a surprising observation: some patients responded to treatment even at a very low dose. Could an additional unknown S1PR1 mechanism support the drug's effectiveness?

"We set out to find this new pathway," said Rosen.

Discovering the Pathway

By isolating immune cells from mice expressing a fluorescently tagged S1PR1 receptor, the researchers found that S1PR1 agonists directly target immune cells called plasmacytoid dendritic cells (pDCs) to slow the overproduction of proteins known to cause autoimmune disease. Normally, these proteins, type-1 interferons, are helpful, stimulating the body to fight off infections. In autoimmune disease, however, they begin an auto-amplification loop that can make the immune system turn on itself.

When agonists stimulate S1PR1 signaling, the S1PR1 receptor is internalized in a cell structure called a vesicle and may be moved to a different part of the cell for degradation. Using CYM-5442, the researchers found when this happens in pDCs, the migrating S1PR1 induces the type-1 interferon receptor (IFNAR1) to turn over and be degraded as well. "IFNAR1 hitches a ride," explained Teijaro, who was first author of the new study with TSRI Research Associate Sean Studer.

With the IFNAR1 receptor degraded, type-1 interferons cannot begin the auto-amplification loop. In follow-up experiments, the researchers observed the same phenomenon in human pDCs isolated from donor blood samples.

"Sphingosine 1-phosphate modulation of the interferon auto-amplification loop by induced turnover of the IFNAR1 is a potential mechanism to limit excessive inflammation physiologically," said Rosen. "Augmentation of this mechanism by drugs like ozanimod may allow the successful treatment of patients with difficult-to-treat characterized by iterferon-a signatures, such as subsets of patients with systemic lupus and rheumatoid arthritis."

Preserving Disease-Fighting Ability

The new study also shed light on the mechanism through which models treated with S1PR1 agonists still recognize and fight off bacteria and viruses, an observation seen in previous studies from the Rosen and Oldstone laboratories.

In the new study, the researchers subjected mouse models to an "immune challenge" by infecting them with the influenza virus. When treated with a S1PR1 agonist, the mouse pDCs still released an initial batch of antiviral type-1 interferon without triggering the auto-amplification loop.

This means the mice fought the infection without overproducing the type-1 interferons that can lead to autoimmune disease.

For human patients, the researchers see a potential advantage in using agonists such as ozanimod to limit immune tissue damage while preserving a patient's ability to protect against opportunistic infections.

In addition to Rosen, Oldstone, Teijaro and Studer, authors of the study, "S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell Interferon-α auto-amplification," were Nora Leaf, William B. Kiosses and Nhan Nguyen of TSRI; and Kosuki Matsuki, Hideo Negishi and Tadatsugu Taniguchi of the University of Tokyo.

Explore further: Scientists describe deadly immune 'storm' caused by emergent flu infections

More information: S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification, PNAS,

Related Stories

Scientists describe deadly immune 'storm' caused by emergent flu infections

February 27, 2014
Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a "cytokine storm"—that can both sicken and kill patients who are infected with certain strains of flu virus.

Scientists identify interferon beta as likely culprit in persistent viral infections

May 13, 2015
Interferon proteins are normally considered virus-fighters, but scientists at The Scripps Research Institute (TSRI) have found evidence that one of them, interferon beta (IFNβ), has an immune-suppressing effect that can ...

MS drug candidate also shows promise for ulcerative colitis

October 28, 2014
Positive new clinical data were released today on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute (TSRI).

Researchers answer long-standing question about lupus

December 7, 2015
For years, biomedical researchers have suspected that a specific set of immune cells are responsible for causing disease in lupus patients, but until now they haven't known for sure one way or the other.

Scientists find key element of lupus, suggesting better drug targets

February 4, 2013
A team led by scientists at The Scripps Research Institute (TSRI) has identified specific cellular events that appear key to lupus, a debilitating autoimmune disease that afflicts tens of millions of people worldwide. The ...

Study identifies novel role of mitochondria in immune function

September 18, 2015
Scientists at The Scripps Research Institute (TSRI) have discovered a new role for an enzyme involved in cell death. Their study shows how the enzyme, called RIPK3, relays signals between the cell's mitochondria "powerhouses" ...

Recommended for you

Novel genomic tools provide new insight into human immune system

January 19, 2018
When the body is under attack from pathogens, the immune system marshals a diverse collection of immune cells to work together in a tightly orchestrated process and defend the host against the intruders. For many decades, ...

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

Researchers identify new way to unmask melanoma cells to the immune system

January 16, 2018
system, which enables these deadly skin cancers to grow and spread.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.